Inv16 AML M4Eo Test

Introduction to the Inv16 AML M4Eo Test

The Inv16 AML M4Eo test is a specialized genetic test used primarily in the field of oncology to diagnose acute myeloid leukemia (AML) associated with the inv(16) chromosomal abnormality. This test is vital for identifying specific genetic changes that can influence treatment decisions and patient prognosis.

What the Test Measures

This test detects the presence of the inv(16) genetic mutation, which is linked to a particular subtype of AML. The identification of this mutation is crucial as it helps in determining the most effective treatment strategies for patients diagnosed with this type of leukemia.

Who Should Consider This Test?

Patients exhibiting symptoms of leukemia, such as unexplained fatigue, frequent infections, or easy bruising, should consider this test. Additionally, individuals with a family history of blood disorders or those who have been exposed to certain risk factors, such as chemical exposure or previous chemotherapy, may also benefit from testing.

Benefits of Taking the Test

• Provides accurate diagnosis of AML associated with the inv(16) mutation.
• Guides oncologists in selecting the most effective treatment plan tailored to the patient’s genetic profile.
• Helps in monitoring the disease’s progression and response to treatment.

Understanding Your Results

Results from the Inv16 AML M4Eo test are generally available within 3-4 days. A positive result indicates the presence of the inv(16) mutation, which may necessitate a specific treatment approach. It is essential to discuss your results with your healthcare provider to understand their implications fully.

Test Pricing

Booking the Test

To book the Inv16 AML M4Eo test, a doctor’s prescription is required. Please note that this prescription is not applicable for patients undergoing surgery, pregnancy cases, or those planning to travel abroad. For more information or to schedule your test, please contact us at +2348077798758.